News
7.9.23

TOPADUR has been selected as a TOP 100 Scale-up 2023 with unicorn potential

Zurich-Schlieren, Switzerland, 7 September 2023

We are thrilled to announce that TOPADUR Pharma AG has once again been recognized as one of Switzerland's top 25 scale-up companies.

This achievement is a demonstration to our team's dedication and our partners' support.

We are grateful for this recognition and remain committed to pushing the boundaries of innovation in the years to come.

Please check out the link below.

Download DocumentDokument herunterladenTOP 25 scale-ups 2023TOP 25 scale-ups 2023
2.11.23
News

TOPADUR, Yonsei University and Juvic Inc. grant awarded

TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with Yonsei University and Juvic Inc.

Read more
10.9.20
Press Release

TOPADUR starts clinical development of a new wound healing drug

TOPADUR Pharma AG announces dosing of first healthy subjects in Phase 1 clinical trial of TOP-N53.

Read more
23.3.22
Press Release

European Patent Office to Grant TOPADUR’s Patent Application for TOP-N53

The European Patent Office granted a patent covering the lead drug candidate, TOP-N53 used for the treatment of chronic wounds.

Read more